Guggenheim Reaffirms Their Buy Rating on ProKidney (PROK)
Guggenheim analyst reiterated a Buy rating on ProKidney yesterday and set a price target of $6.00. The company’s shares closed yesterday at $3.73.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ProKidney with a $3.00 average price target, a -19.57% downside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $9.00 price target.
Based on ProKidney’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $230 thousand and a GAAP net loss of $16.73 million. In comparison, last year the company had a GAAP net loss of $9.49 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PROK in relation to earlier this year. Most recently, in April 2025, Carso De-C Inmobiliaria, a Major Shareholder at PROK bought 387,393.00 shares for a total of $275,049.03.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- Why Is ProKidney Stock (PROK) Up 60% Today?
- ProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties
- Hold Rating for ProKidney Amid Promising Phase 2 Results and Regulatory Uncertainty
- ProKidney price target raised to $9 from $6 at Citi
- ProKidney move after REACT update ‘looks overdone,’ says BofA
